[Federal Register Volume 77, Number 97 (Friday, May 18, 2012)]
[Notices]
[Page 29676]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2012-12012]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Diabetes and Digestive and Kidney 
Disorders; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.) notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The purpose of this meeting is to evaluate requests 
for preclinical development resources for potential new therapeutics 
for type 1 diabetes. The outcome of the evaluation will be a decision 
whether NIDDK should support the request and make available contract 
resources for development of the potential therapeutic to improve the 
treatment or prevent the development of type 1 diabetes and its 
complications. The research proposals and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the proposed research projects, the disclosure of which 
would constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: Type 1 Diabetes--Rapid Access to Intervention 
Development Special Emphasis Panel; National Institute of Diabetes 
and Digestive and Kidney Diseases.
    Date: June 21, 2012.
    Time: 3:00 p.m.-5:00 p.m.
    Agenda: To evaluate requests for preclinical development 
resources for potential new therapeutics for type 1 diabetes and its 
complications.
    Place: 6707 Democracy Boulevard, Bethesda, MD 20892, (Telephone 
Conference Call).
    Contact Person: Dr. Aaron Pawlyk, Program Director for 
Pharmacogenomics and Drug Discovery, National Institute of Diabetes 
and Digestive and Kidney Diseases, Building 2DEM, Room 788B, 6707 
Democracy Boulevard, Bethesda, MD 20892, Tel: 301-451-7299, Fax: 
301-480-0475, Email: [email protected].

    Name of Committee: Type 1 Diabetes--Rapid Access to Intervention 
Development Special Emphasis Panel; National Institute of Diabetes 
and Digestive and Kidney Diseases.
    Date: June 22, 2012.
    Time: 10:00 p.m.-12:00 p.m.
    Agenda: To evaluate requests for preclinical development 
resources for potential new therapeutics for type 1 diabetes and its 
complications.
    Place: 6707 Democracy Boulevard, Bethesda, MD 20892, (Telephone 
Conference Call).
    Contact Person: Dr. Aaron Pawlyk, Program Director for 
Pharmacogenomics and Drug Discovery, National Institute of Diabetes 
and Digestive and Kidney Diseases, Building 2DEM, Room 788B, 6707 
Democracy Boulevard, Bethesda, MD 20892, Tel: 301-451-7299, Fax: 
301-480-0475, Email: [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, 
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive 
Diseases and Nutrition Research; 98.849, Kidney Diseases, Urology 
and Hematology Research, National Institutes of Health, HHS)

    Dated: May 11, 2012.
Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2012-12012 Filed 5-17-12; 8:45 am]
BILLING CODE 4140-01-P